1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Getinge AB (publ)

Getinge AB (publ)

0GZV.IL
Getinge AB (publ)GB flagInternational Order Book
205.80
SEK
+0.15
- -
56.57BMarket Cap
Getinge AB (publ)
0GZV.IL
(International Order Book)

Recent

price

205.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
87.71
86.46
95.93
100.04
105.5
119.61
91.7
89.72
88.75
97.51
109.48
99.31
103.87
116.85
127.62
128.38
130.33
Revenue per Share
9.01
10
9.97
9.04
5.67
5.5
4.91
5.49
-3.55
4.49
11.89
10.9
9.15
8.86
6.01
8.29
5.47
Basic EPS, GAAP
11.32
8.85
7.84
7.36
10.2
6.76
9.29
4.39
9.19
9.59
22.59
20.67
8.19
5.89
12
9.67
9.93
Free Cash Flow per Basic Share
2.59
3.07
3.54
3.91
3.93
2.73
2.83
1.97
1.56
1.09
1.59
3.15
4.08
4.34
4.5
4.65
4.68
Dividend per Share
32.27
39.65
44.98
49.7
49.59
52.38
56.22
49.57
41.04
43.11
53.45
61.37
69.51
73.42
75.13
79.45
73.76
Book Value per Share
-23.64
-39.01
-38.35
-33.89
-44.98
-43.32
-45.86
-12.92
-16.31
-12.15
-2.2
3.77
12.64
-0.98
-22.14
-14.76
-20.82
Tangible Book Value per Share
253
253
253
253
253
253
242
251
272
272
272
272
272
272
272
272
272
Basic Weighted Avg Shares
22,172
21,854
24,248
25,287
26,669
30,235
22,170
22,495
24,172
26,559
29,819
27,049
28,291
31,827
34,759
34,968
35,499
Sales/Revenue/Turnover
17.45
18.76
17.46
16.46
14.42
11.31
12.08
10.03
-1.17
10.19
16.87
16.07
13.7
11.61
10.63
12.77
10.8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
2,703
2,609
1,808
2,223
2,467
1,814
2,027
2,093
2,422
2,250
2,538
Depreciation Expense
2,277
2,529
2,521
2,285
1,433
1,390
1,188
1,376
-967
1,222
3,239
2,970
2,491
2,412
1,638
2,258
1,490
Net Income, GAAP
26.83
26.34
26.34
27.21
27.13
27.04
26.15
- -
- -
34.21
27.05
28.34
27.53
27.37
27.52
27.63
27.96
Effective Tax Rate (%)
10.27
11.57
10.4
9.04
5.37
4.6
5.36
6.12
-4
4.6
10.86
10.98
8.8
7.58
4.71
6.46
4.2
Profit Margin (%)
4,935
5,241
3,070
4,029
1,630
3,880
3,896
2,292
4,143
4,630
7,643
4,459
7,113
3,462
3,115
4,185
2,880
Working Capital
11,411
15,121
13,163
13,566
14,378
16,006
15,914
4,962
7,378
7,068
7,687
3,495
5,031
4,960
8,280
8,922
8,975
LT Debt
13,248
14,636
15,200
16,560
18,694
19,593
20,916
19,806
19,655
20,973
21,486
25,176
30,453
30,403
33,210
29,493
29,018
Total Equity
10.32
10.54
9.71
9.11
7.68
6.24
4.76
- -
- -
5.79
11.68
10.12
8.48
7.14
6.47
7.6
6.86
Return on Invested Capital (%)
12.27
12.01
10.46
9.19
5.97
5.39
4.35
- -
- -
6.54
14.28
13.06
11.22
10.23
6.9
8.5
4.89
Return on Capital (%)
30.51
27.82
23.57
19.09
11.42
10.79
8.85
10.58
-8.19
10.66
24.63
18.99
13.98
12.39
8.1
10.73
7.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,447
2,219
2,194
LT Borrowings
6,971
8,118
7,910
LT Finance Leases
1,309
1,145
1,065
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
272
272
272
Market Capitalization
49,484
58,995
51,282

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
18,162
18,164
15,733
Cash, Cash Equivalents & STI
2,961
4,203
1,945
Accounts Receivable, Net
6,348
5,265
4,785
Inventories
6,590
6,650
6,793
Total Current Liabilities
15,047
13,888
12,853
Payables & Accruals
- -
- -
- -
ST Debt
2,447
2,219
2,194
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.59%
7.2%
-11.19%
Free Cash Flow
23.52%
-2.52%
-19.37%
Net Income, GAAP
-25.21%
-4.37%
37.85%
Sales/Revenue/Turnover
2.2%
3.52%
0.6%
Total Cash Common Dividend
11.37%
28.22%
3.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,513
8,305
7,870
11,071
34,759
2025
8,320
8,238
10,186
- -
34,968
2026
7,443
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.69
1.88
0.01
2.44
6.01
2025
1.1
1.92
3.19
- -
8.29
2026
1.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
4.44
0.02
0.04
4.5
2025
- -
4.62
0.01
- -
4.65
2026
- -
- -
- -
- -
- -
Similar Companies
Positron Corporation (POSC)
Profound Medical Corp. (PROF)
IceCure Medical Ltd (ICCM.TA)
PAVmed Inc (PAVMZ)
Soliton, Inc. (SOLY)
CYBERDYNE Inc. (CYBQY)
Business
Getinge AB (publ) is a global medical technology company that develops, manufactures and markets innovative solutions for operating rooms, intensive care units, cardiovascular procedures, sterile reprocessing, and life science applications. The company offers products including hemodynamic monitoring systems such as the Pulsiocare monitor; vessel harvesting systems like Vasoview 6 Pro; low-temperature sterilizers including Poladus 150; ultrasonic cleaning units such as Getinge Elmasonic Med and pre-treatment foams like Getinge Clean; drying and storage cabinets including Getinge EDS8; washers such as GEW 888 neo; sterile transfer bags like DPTE-BetaBag; clinical decision support software including Talis; covered stent systems such as Advanta V12; ECMO therapy consumables including HLS and PLS sets; organ preservation and transportation technologies; as well as digital health solutions, services for equipment maintenance, financial planning, project implementation, education and training. Getinge operates through three main business areas—Acute Care Therapies, Surgical Workflows, and Life Science—serving hospitals, life science institutions, and biopharmaceutical manufacturers worldwide, with sales in more than 135 countries, operations in 40 countries, and production facilities in France, China, Germany, Poland, Sweden, Turkey, Netherlands, UK and the US. Founded in 1904 in Getinge, Sweden, and headquartered in Gothenburg, Sweden, the company employs approximately 12,000 people and is listed on Nasdaq Stockholm. In recent developments, Getinge completed the acquisition of Paragonix Technologies in September 2024 for approximately USD 477 million to strengthen its organ transplantation portfolio; acquired Healthmark in October 2023, HPNE in May 2023, and Ultra Clean Systems in April 2023 to expand sterile reprocessing and life science offerings; launched Poladus 150 sterilizer, Talis software with 510(k) clearance, Advanta V12 with EU MDR approval, GEW 888 neo washer, and a sustainable DPTE-BetaBag version in 2024; and updated its financial targets for adjusted EPS growth above 12% annually through 2028 while advancing next-generation Cardiohelp and Cardiosave systems for regulatory submission in 2025.